Novo Nordisk: A Sweet Treat, Not a Spoiled Plum

Novo Nordisk Research

Now, listen closely. There’s a rather peculiar fuss going on in the world of potions and pills, all thanks to these new weight-loss concoctions. Novo Nordisk (NVO 0.51%) was the first to stumble upon the magic, but then along came Eli Lilly (LLY +1.03%), waving a slightly shinier, more captivating potion. Wall Street, predictably, went absolutely bonkers, ditching Novo Nordisk like a half-eaten Brussels sprout and clamoring for Lilly. But here’s the rub: sometimes, the slightly less sparkly plum is the one with the sweetest juice inside. If you’re patient, that is.

Wall Street and its Wobbly Knees

Investors, you see, are rather like a flock of excitable pigeons. They spot a shiny crumb (a hot stock) and dive for it, flapping and squawking until the crumb is nothing but dust. This is precisely what’s happening with these GLP-1 potions. Everyone’s rushing in, convinced they’ve discovered the elixir of eternal riches. It’s a bit silly, really.

Novo Nordisk brewed up Ozempic, a potion that helped those with a sugar-plum problem, and then a stronger version, Wegovy, for those who simply wished to shrink. Then Lilly arrived with Mounjaro and Zepbound, potions that seemed to work even better. Naturally, Novo Nordisk’s stock wobbled, while Lilly’s soared. It’s a predictable pattern, like rain following clouds.

Stock Performance Chart

There’s nothing terribly shocking about this, mind you. Wall Street operates on whims and whispers. But when stocks do a jig up and down, it’s worth a peek under the rug.

One must consider ‘valuation’ – a fancy word for figuring out if something is worth the price. It’s more art than science, really. Lilly’s price-to-earnings ratio (P/E) is a lofty 50, a bit like a tower built on marshmallows. Novo Nordisk’s is a more sensible 18. Lilly’s is slightly below its usual silliness, but Novo Nordisk’s is considerably cheaper, both now and compared to its past antics. And Novo Nordisk offers a generous 2.8% dividend – a lovely little treat – while Lilly offers a miserly 0.6%.

Novo Nordisk: More Than Just a Potion-Brewer

Now, it’s true that Novo Nordisk isn’t currently the king of the potion castle. But they are a clever bunch, nonetheless. They were the first to create a GLP-1 pill – a small, swallowable marvel. People generally prefer pills to injections, you see. It’s less…prickly. This gives Novo Nordisk a chance to reclaim some territory, although Lilly is brewing up its own pill, so the advantage won’t last forever.

This is the competitive nature of the potion business. Lilly won’t be on top forever. And look, even Pfizer (PFE +0.11%) is scrambling to create its own potions, using all sorts of tricks and partnerships to speed things up. A right old scramble, it is.

Which is why you might consider snatching up Novo Nordisk while it’s at a bargain price. But the real secret is that they make more than just weight-loss potions. They are also masters of the sugar-plum potion – insulin. While the weight-loss potions are flashy, the demand for insulin is constant. It’s a reliable source of income, like a well-tended garden.

In fact, they only send out about 40% of their profits as dividends – a comfortable amount. This suggests that the dividend is quite secure, a lovely little cushion against any future mishaps.

A Bargain Worth a Nibble

Novo Nordisk has leaped ahead with its pill, but that’s not the main reason to like the stock. If you’re a dividend-lover or prefer a sensible price, this stock should look rather appealing. The potion business will ebb and flow, but Novo Nordisk’s core business – helping those with sugar-plum problems – remains a solid foundation for both the dividend and the company’s long-term growth. A sweet treat, indeed.

2026-02-02 21:54

Wall Street and its Wobbly Knees

Novo Nordisk: More Than Just a Potion-Brewer

A Bargain Worth a Nibble

Read More